ALNYLAM PHARMACEUTICALS, INC.
ALNY · XNASCIK 1178670fmd_0PJDK7HC2173VZ2KNEG77WE2KSManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2008 to Sep 30, 2026, 71 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 47 | 90 | 75 | 220 | 493 | 844 | 1,037 | 1,828 | 2,248 | 3,714 |
| Cost of revenue | – | 0 | 2 | 25 | 74 | 115 | 140 | 268 | 307 | 677 |
| Gross profit | – | 90 | 73 | 195 | 419 | 729 | 897 | 1,560 | 1,942 | 3,037 |
| Research and development | 382 | 391 | 505 | 655 | 655 | 792 | 883 | 1,004 | 1,126 | 1,320 |
| Selling, general and administrative | 89 | 199 | 382 | 479 | 588 | 621 | 771 | 796 | 976 | 1,211 |
| Total operating expenses | 472 | 590 | – | – | – | – | – | – | – | – |
| Operating income | (425) | (500) | (815) | (939) | (828) | (709) | (785) | (282) | (177) | 502 |
| Interest expense | – | – | 0 | 0 | 84 | 143 | 156 | 121 | 142 | 253 |
| Interest and investment income | – | – | 29 | 33 | 12 | 2 | 25 | 96 | 122 | 111 |
| Other non-operating income (expense) | 14 | 9 | 54 | 54 | (27) | (143) | (342) | (151) | (200) | (178) |
| Income before taxes | (410) | (491) | (761) | (885) | (856) | (852) | (1,127) | (434) | (377) | 323 |
| Income tax expense | 0 | 0 | 1 | 1 | 3 | 1 | 4 | 7 | (99) | 9 |
| Net income from continuing operations | (410) | (491) | (761) | (886) | (858) | (853) | (1,131) | (440) | (278) | 314 |
| Net income | (410) | (491) | (761) | (886) | (858) | (853) | (1,131) | (440) | (278) | 314 |